Publication: Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma
Issued Date
2015
Resource Type
Language
eng
Rights
Mahidol University
Rights Holder(s)
BioMed Central
Bibliographic Citation
Thyroid Research. Vol. 8, (2015), 11
Suggested Citation
Surasawadee Ausavarat, Jiraporn Sriprapaporn, Busara Satayaban, Wanna Thongnoppakhun, Aunchalee Laipiriyakun, Boontham Amornkitticharoen, Rujaporn Chanachai, Chaveevan Pattanachak Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma. Thyroid Research. Vol. 8, (2015), 11. doi:10.1186/s13044-015-0024-4 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/2672
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma
Abstract
Background: Circulating thyrotropin receptor messenger ribonucleic acid (TSHR mRNA) assay has been validated
in the follow-up of differentiated thyroid carcinoma (DTC) because of its high sensitivity during thyroid hormone
therapy and no interference with endogenous anti-thyroglobulin antibodies (TgAb) compared to serum thyroglobulin
(Tg). We investigated the efficacy of TSHR mRNA assay in 160 DTC patients using quantitative PCR (qPCR).
Findings: Only TSHR mRNA level of structural persistent disease with TgAb-positive (3.47 (2.97–9.53) pg equivalents/μg
total RNA; p = 0.013) and its subgroup of distant metastasis patients with TgAb-positive (5.55 (3.28–12.52) pg equivalents/
μg total RNA; p = 0.009) were significantly different from patients with no evidence of disease (2.32 (1.44–3.94)
pg equivalents/μg total RNA). Applying cutoff at 2.00 pg equivalents/μg total RNA enabled us to predict
structural persistent disease patients with a sensitivity of 62.3 % and a specificity of 42.9 %. Although, the
sensitivity of TSHR mRNA assay in TgAb-postive patients (88.2 %) was superior than serum Tg (47.1 %) (p = 0.00002), the
accuracy of the test is only 54.5 %.
Conclusions: This study demonstrated that TSHR mRNA assay has good sensitivity in TgAb-positive patients but it is
neither specific enough as a first-line of testing nor a surrogate marker in the follow-up of our DTC patients.